Insmed Incorporated (NASDAQ:INSM) Shares Sold by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust decreased its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 17.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 400,624 shares of the biopharmaceutical company's stock after selling 87,040 shares during the period. Insmed accounts for 1.7% of Emerald Mutual Fund Advisers Trust's investment portfolio, making the stock its 10th biggest holding. Emerald Mutual Fund Advisers Trust owned approximately 0.22% of Insmed worth $27,659,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in INSM. Steward Partners Investment Advisory LLC lifted its stake in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 163 shares during the period. V Square Quantitative Management LLC increased its holdings in shares of Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 248 shares in the last quarter. Spire Wealth Management acquired a new position in shares of Insmed during the fourth quarter worth about $47,000. Smartleaf Asset Management LLC raised its stake in shares of Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in Insmed during the fourth quarter worth $86,000.

Insmed Stock Performance

INSM stock traded up $0.64 during trading on Thursday, hitting $72.64. The company had a trading volume of 1,792,909 shares, compared to its average volume of 2,309,498. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a 50-day moving average price of $73.67 and a 200-day moving average price of $73.51. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The firm has a market cap of $13.21 billion, a PE ratio of -12.99 and a beta of 1.07.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to analysts' expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Activity at Insmed

In other news, CEO William Lewis sold 6,830 shares of the stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the completion of the sale, the chief executive officer now directly owns 233,924 shares of the company's stock, valued at $16,412,107.84. This represents a 2.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Sara Bonstein sold 28,390 shares of Insmed stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $80.90, for a total transaction of $2,296,751.00. Following the completion of the sale, the chief financial officer now owns 155,506 shares of the company's stock, valued at $12,580,435.40. This trade represents a 15.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 380,657 shares of company stock worth $30,330,039 in the last ninety days. 3.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on INSM. UBS Group boosted their target price on shares of Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Guggenheim reissued a "buy" rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. Stifel Nicolaus dropped their target price on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a report on Friday, February 21st. Morgan Stanley upped their price objective on Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat, Insmed presently has an average rating of "Moderate Buy" and an average price target of $94.00.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.